Title Randomized Trial of Hypofractionated LocoRegional Radiotherapy in Breast Cancer and Lymphedema
Protocole ID RHEAL
ClinicalTrials.gov ID NCT04228991
Cancer Type(s) Breast
Phase Phase III
Stage
Study Type Clinical
Drug
Institution CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
City
Principal Investigator Dr. Pierre Rousseau
Coordinator Mom Phat
514-890-8000 poste 11171
Status Recruiting
Activation Date
Eligibility Criteria
  • Newly diagnosed invasive carcinoma of the breast.
  • Treated with definitive surgery (BCS or mastectomy with nodal staging using SLNB or ALND) with clear margins of excision.*
    Note: *Patients with limited positive posterior margin where disease is resected to chest wall or limited positive anterior margin where disease is resected to dermis are eligible.
  • Breast cancer stage after definitive surgery.
    Note: †Patients who are histologically node positive prior to chemotherapy and who have complete response in the lymph nodes are eligible.
    • if neoadjuvant chemotherapy was not administered: pathologic stage T1-3, N1-2
    • if neoadjuvant chemotherapy was administered: clinical stage T1-3, N1-2 (histologically node positive) and pathologic stage T0-3, N0-2†
  • No evidence of metastatic disease.
  • Candidate for locoregional radiotherapy.
Exclusion Criteria
  • Age < 18 years.
  • Clinical stages T4 and/or N3.
  • Clinical lymphedema in the ipsilateral arm or breast/chest wall.
  • Synchronous or previous contralateral breast cancer.
  • Breast reconstruction.
  • History of non-breast malignancy within the last 5 years other than non-melanoma skin cancer or treated in-situ carcinoma.
  • Previous radiotherapy to the ipsilateral breast or chest wall or serious non-malignant disease e.g. scleroderma, severe lung or heart disease that would preclude radiotherapy.
  • Known pregnancy or currently lactating.
  • Geographic inaccessibility for follow-up.
  • Inability to provide informed consent.